Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

References

• Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763–13. doi:10.1016/j.it.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. doi:10.1038/nri3156.
   PubMed Web of Science ®Google Scholar
• Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297–302. doi:10.2174/092986710793176410.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. doi:10.1080/2162402X.2016.1163462.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–58. doi:10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• D’Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6(11):1152–59. doi:10.1038/ni1264.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6(11):1142–51. doi:10.1038/ni1263.
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat Immunol. 2005;6(11):1071–72. doi:10.1038/ni1105-1071.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Russell J. The regulation of FasL expression during activation-induced cell death (AICD). Immunology. 2001;103(4):426–34. doi:10.1046/j.1365-2567.2001.01264.x.
   PubMed Web of Science ®Google Scholar
• Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8(5):615–23. doi:10.1016/S1074-7613(00)80566-X.
   PubMed Web of Science ®Google Scholar
• Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, Shablak A, Shanks J, Liptrot T, Thistlethwaite F, et al. High-dose interleukin 2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. J Immunother Cancer. 2016;4:67. doi:10.1186/s40425-016-0174-5.
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293–301. doi:10.1002/cncr.23552.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Cheng S-C, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561–68. doi:10.1158/1078-0432.CCR-14-1520.
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14(17):5610–18. doi:10.1158/1078-0432.CCR-08-0116.
   PubMed Web of Science ®Google Scholar
• Prometheus Laboratories, Inc. San Diego, CA 92121. Proleukin® (aldesleukin) Package Insert. 2012.
   Google Scholar
• Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA. 2010;107(26):11906–11. doi:10.1073/pnas.1002569107.
   PubMed Web of Science ®Google Scholar
• Ledford H. Old cancer drug gets fresh look. Nature. 2014;509(7502):541–42. doi:10.1038/509541a.
   PubMed Web of Science ®Google Scholar
• Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013;13(1):20. doi:10.1186/1471-2407-13-20.
   PubMedGoogle Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009. doi:10.1007/s00262-015-1704-6.
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lo K-M, Burger C, Lan Y, Dahl T, Wong W-K. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res. 2002;8:210–16.
   PubMed Web of Science ®Google Scholar
• Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res. 2001;7:2862–69.
   PubMed Web of Science ®Google Scholar
• King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004;22(22):4463–73. doi:10.1200/JCO.2004.11.035.
   PubMed Web of Science ®Google Scholar
• Schwager K, Hemmerle T, Aebischer D, Neri D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013;133:751–58. doi:10.1038/jid.2012.376.
   PubMed Web of Science ®Google Scholar
• Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969–75. doi:10.1200/JCO.2009.27.8861.
   PubMed Web of Science ®Google Scholar
• Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci USA. 2015;112:3320–25. doi:10.1073/pnas.1416159112.
   PubMed Web of Science ®Google Scholar
• Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res. 2014;2:668–78. doi:10.1158/2326-6066.CIR-13-0206.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306. doi:10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257–66. doi:10.1158/1535-7163.MCT-11-0340.
   PubMed Web of Science ®Google Scholar
• Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–63. doi:10.1002/prca.201300095.
   PubMed Web of Science ®Google Scholar
• Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther. 2012;13(3):123–29. doi:10.4161/cbt.13.3.18696.
   PubMed Web of Science ®Google Scholar
• Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160–67. doi:10.2967/jnumed.120.244806.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–05. doi:10.2967/jnumed.119.227967.
   PubMed Web of Science ®Google Scholar
• Laverman P, Van Der Geest T, Terry SYA, Gerrits D, Walgreen B, Helsen MM, Nayak TK, Freimoser-Grundschober A, Waldhauer I, Hosse RJ, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med. 2015;56(5):778–83. doi:10.2967/jnumed.114.152959.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–30. doi:10.4161/mabs.3.5.16983.
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–66. doi:10.4161/mabs.3.1.13799.
   PubMed Web of Science ®Google Scholar
• Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–32. doi:10.1136/gutjnl-2016-311585.
   PubMed Web of Science ®Google Scholar
• Rivera IO, Iclozan C, McGill A, Ghansah T. PD-L1/PD-1 Immunotherapy modulates effector T cells homeostasis and function in murine pancreatic cancer. J Immunol. 2016;196:72.11–72.11.
   PubMed Web of Science ®Google Scholar
• Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):680–90. doi:10.1158/1078-0432.CCR-15-1631.
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704. doi:10.1016/S1470-2045(18)30148-7.
   PubMed Web of Science ®Google Scholar
• Miller JS, Cooley S, Holtan S, Arora M, Ustun C, Jeng E, Wong HC, Verneris MR, Wagner JE, Weisdorf DJ, et al. First-in-human phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. Blood. 2015;126:1957. doi:10.1182/blood.V126.23.1957.1957.
   Web of Science ®Google Scholar
• Akimzhanov AM, Wang X, Sun J, Boehning D. T-cell receptor complex is essential for Fas signal transduction. Proc Natl Acad Sci USA. 2010;107(34):15105–10. doi:10.1073/pnas.1005419107.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini V, Dunn C, Freimoser-Grundschober A, Herter S, Geven E, Boerman O, Nayak T, Puijenbroek E, et al. Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer. Cancer Res. 2013;73:486–486.
   Web of Science ®Google Scholar
• Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. doi:10.1080/2162402X.2016.1203498.
   PubMed Web of Science ®Google Scholar
• Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22(13):3286–97. doi:10.1158/1078-0432.CCR-15-1696.
   PubMed Web of Science ®Google Scholar
• Melero I, Castanon Alvarez E, Mau-Sorensen M, Lassen UN, Lolkema MP, Robbrecht DG, Gomez-Roca CA, Martin-Liberal J, Tabernero J, Ros W, et al. Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v) (Abstract 412PD). Ann Oncol. 2018;29:viii134. doi:10.1093/annonc/mdy279.400.
   Web of Science ®Google Scholar
• Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med. 2012;53(1):113–20. doi:10.2967/jnumed.111.094169.
   PubMed Web of Science ®Google Scholar